Adverse Effects

Latest News

Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis
Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis

March 24th 2023

Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.

Investigators indicate that strategies are necessary to identify patients with extensive-stage small cell lung cancer who won’t benefit from immunotherapy-based treatment.
IO/Chemo Associated With Higher Toxicity Risk in ES-SCLC

March 14th 2023

Abatacept plus ruxolitinib and screenings for concomitant respiratory muscle failure may be effective in reducing the rate of mortality related to immune checkpoint inhibitor–associated myocarditis among patients with cancer.
Abatacept Combo May Reduce Immunotherapy-Related Myotoxicity in Cancer

March 8th 2023

A prefilled autoinjector presentation of Pegfilgrastim-cbqv, a pegfilgrastim biosimilar, has been approved by the FDA for patients with cancer undergoing chemotherapy who may experience febrile neutropenia.
FDA Approves Pegfilgrastim Biosimilar to Mitigate Febrile Neutropenia From Chemo

March 6th 2023

In particular, female patients who were considered obese with an advanced malignancy seem to have a higher incidence of high-grade immune-mediated adverse effects following treatment with nivolumab.
Nivolumab May Yield More IRAEs in Those With Cancer Who Have a Higher BMI

March 5th 2023

More News